


COMPLETE LISTING OF CLAIMS PURSUANT TO 37 C.F.R. §1.121

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend the claims as follows. The following listing of amended claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) [Application of] A method of treating a wound in an animal or human comprising administering to said animal or human a pharmaceutical composition comprising a lipopeptide or lipoprotein with the following general structure:



[in which] wherein

R^1 and R^2 [, which can be the same or different,] stand for C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkinyl,

X is S, O₂ or CH₂,

Z^1 and Z^2 [, which can be the same or different,] stand for H or methyl,

W stands for CO or S(O)_n (where n = 1 or 2) and

Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues and the asymmetric carbon atom marked with * denotes an asymmetric carbon atom and has the absolute configuration S R when X = S (sulfur) [, for the preparation of a pharmaceutical preparation for treatment of wounds in animals or humans].

2. (Currently Amended) [Application according to] The method of Claim 1, [characterized by the fact that] wherein Y [stands for a physiologically compatible] comprises an amino acid sequence consisting of 1 to 25 amino acids.

3. (Currently Amended) [Application according to] The method of Claim 1, [characterized by the fact that] wherein Y [stands for] comprises an amino acid sequence which is selected from the [following] group consisting of:

- (i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein;
- (ii) GQTNT (SEQ ID NO:1);
- (iii) SKKKK (SEQ ID NO:2);
- (iv) GNNDESNISFKEK (SEQ ID NO:3);
- (v) GQTDNNSQSQQPGSGTTNT (SEQ ID NO:4);

[where, in amino acid sequences (ii), (iii), (iv) and (v), individual amino acids may be absent or replaced] or a fragment or variant of the amino acid sequences in (ii), (iii), (iv) and (v) wherein said fragment or variant has macrophage stimulating activity.

4. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1[, where] wherein the C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl, or C₇₋₂₅-alkinyl is a C₁₅-alkyl, C₁₅-alkenyl or C₁₅-alkinyl, respectively.

5. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1[, where] wherein the double bond(s) in the C₇₋₂₅-alkenyl group has(have) the cis-configuration.

6. (Currently Amended) [Application of] A method of treating a wound in an animal or human comprising administering to an animal or human a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two[, optionally long-chain], fatty acids bonded via ester bonds[, which wherein said fatty acids may can be the same or different, for the preparation of a pharmaceutical preparation for the treatment of animal and human wounds].

7. (Currently Amended) [Application of] The method of claim 1 wherein said lipopeptide or lipoprotein [obtainable] is obtained from a mycoplasma clone [for the treatment of wounds in animals or humans].

8. (Currently Amended) [Application according to] The method of Claim 7, [characterized by the fact that the] wherein said lipopeptide or lipoprotein [can be] is obtained from a *Mycoplasma fermentans* clone.

9. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1 wherein said[, where] the lipopeptide or lipoprotein is water-soluble or amphoteric.

10. (Currently Amended) [Application according to one of the previous Claims of a] The method of claim 1 wherein said lipopeptide or lipoprotein selected from the group consists of:

(i) S-[2,3-bisphosphatidyl-(2RS)-propyl]cysteinyl-GQTNT (SEQ ID NO:5)

(ii) S-[2,3-bisphosphatidyl-(2RS)-propyl]cysteinyl-SKKKK (SEQ ID NO:6)

(iii) S-[2,3-bisphosphatidyl-(2RS)-propyl]cysteinyl-
GNNDESNISFKEK (SEQ ID NO:7)

(iv) S-[2,3-bisphosphatidyl-(2S)-propyl]cysteinyl-
GNNDESNISFKEK (SEQ ID NO:8)

(v) S-[2,3-bisphosphatidylpropyl]cysteinyl-
GQTDNNSQSQQPGSGTTNT (SEQ ID NO:9) and

(vi) S-[2,3-bisphosphatidyl-(2R)-propyl]cysteinyl-
GNNDESNISFKEK (SEQ ID NO:10).

11. (Currently Amended) [Application according to one of the previous Claims, where the] The method of claim 1 wherein said lipopeptide or lipoprotein [can be] is in the form of a solution for epicutaneous application, an injection solution, a salve, a lotion, an aqueous suspension, a plaster impregnated or coated with [it] said lipopeptide or lipoprotein, encapsulated in liposomes, or coupled to biodegradable carrier polymers.

12. (Currently Amended) [Application according to one of the previous Claims, where the] The method of claim 1 wherein said wounds [being] are wounds after

injury or surgical intervention, chronically infected wounds, burn wounds, chronic ulcers or
Ulcus venosum or wounds of patients who are corpulent or diabetic or are subjected to
radiation or chemotherapy.